Introduction
Copy number variation (CNV) of human DNA segments is an important source of genetic diversity and increasing evidence indicates that CNV may underlie disease susceptibility. [1] [2] [3] [4] It is to be noted that there seems to be an enrichment of CNV in immune response genes 1 such that they may contribute to the observed inter-individual variability in susceptibility to infectious diseases, vasculitis and autoimmune diseases. For example, we and others found that the copy number of segmental duplication on chromosome 17q that contains the gene encoding the chemokine CC chemokine ligand 3-like 1 (CCL3L1) influences HIV-AIDS susceptibility, [5] [6] [7] [8] [9] and the risk of developing Kawasaki's disease, 10 systemic lupus erythematosus (SLE) 11 and rheumatoid arthritis (RA). 12 CNV in the gene encoding the complement component C4 and FCGR2C has been associated with SLE 13 and idiopathic thrombocytopenic purpura, 14 respectively. The gene FCGR3B, at chromosome 1q23, encodes the activatory Fc receptor, and a low copy number of this gene has been associated with increased susceptibility to glomerulonephritis in patients with SLE 15 as well as with anti-neutrophil cytoplasmic antibody-associated vasculitis. 13 FCGR3B is expressed on neutrophils and eosinophils, and has an important role in the regulation of inflammatory and immune responses. 16, 17 On the basis of the principle of common variant/multiple diseases (CV/MD), which states that a CV might affect susceptibility to MD, [18] [19] [20] here we determined whether the impact of CNV in FCGR3B extends beyond SLE and affects the risk of other autoimmune diseases such as RA and primary Sjö gren's syndrome (SS). In addition, because the CNV in CCL3L1 influences the risk of SLE and RA, 11, 12 we determined whether this CNV modifies the phenotypic (autoimmune-influencing) effects associated with the CNV in FCGR3B.
In addition to the principle of CV/MD, here we considered whether the gene balance hypothesis would be applicable to the CNV in FCG3RB. This hypothesis postulates that phenotypic consequences occur both when the gene is under-or overexpressed, that is, in genetic states of haploinsufficiency and high gene dosage. 2 We considered this hypothesis might be applicable to FCGR3B, because in our previous studies, we found that a copy number of CCL3L1 that was lower or greater than the average gene dose found in the study population was associated with an increased risk of developing SLE. 11 The results of the present study validate both the concepts of CV/MD and gene balance, because we found that (i) a copy number of FCG3RB that is less than or greater than the population average was associated with an increased risk of developing SLE and primary SS and (ii) the phenotypic effects associated with FCG3RB dose differed depending on the coexisting CCL3L1 gene dose.
Results
The copy number of FCGR3B in subjects with SLE, RA and primary SS ranged from zero to five, with an average gene dose of two copies (Figure 1a) . The distribution of the copy number of FCGR3B differed significantly between controls and SLE or primary SS cases, but not between controls and RA cases (Figure 1a ). This suggested that the CNV of FCGR3B might be a risk factor for development of SLE and primary SS but not RA.
In an earlier study, we found that a CCL3L1 copy number that was greater or lower than the average CCL3L1 gene dose found in the study population (two copies) was associated with an increased risk of developing SLE. 11 We therefore hypothesized that a similar relationship might be applicable to the CNV in FCGR3B such that a copy number that was lower or higher than the average gene dose of FCGR3B (two copies) might associate with an altered risk of developing SLE, primary SS or RA. Consistent with this possibility, possession of a copy number of FCGR3B less than (odds ratio (OR) ¼ 2.41; 95% confidence interval (CI) ¼ 1.41-4.10; P ¼ 0.001) or greater than (OR ¼ 2.15; 95% CI ¼ 1.18-3.93; P ¼ 0.013) two copies was associated with an increased risk of developing SLE (Figure 1b) Figure 1b ). There were no significant differences in the clinical manifestations of patients with less than two copies versus those who had greater than two copies of FCGR3B (data not shown). By contrast to its associations with SLE and SS, we did not detect an association between FCGR3B CNV and risk of developing RA (Figure 1b) .
Possession of a copy number of FCGR3B greater than two was also associated with an increased risk (OR ¼ 2.98; 95% CI 0.98-9.06; P ¼ 0.055) of lupus nephritis. Although possession of less than two copies of FCGR3B was also associated with a trend toward an increased risk of developing lupus nephritis, this association did not reach statistical significance (OR ¼ 1.53; 95% CI ¼ 0.62-3.76; P ¼ 0.353). We did not detect an association between FCGR3B CNV and levels of anti-DNA, anti-Ro and anti-La autoantibody (data not shown).
Independent effects of FCGR3B CNV
We next determined whether the copy number of FCGR3B is associated with the risk of developing SLE and primary SS independent of the effects of the copy number of CCL3L1. 5 To test this, we included CCL3L1 CNVs (o2 and 42) in the same logistic regression model along with the FCGR3B CNVs. After adjusting for the effects of CCL3L1 CNV, deviation from the average FCGR3B gene dose independently associated with the risk of developing SLE (OR ¼ 2.30; 95% CI ¼ 1.35-3.94; P ¼ 0.002 for o2 FCGR3B copies and OR ¼ 2.25; 95% CI ¼ 1.22-4.13; P ¼ 0.009 for 42 FCGR3B copies) and primary SS (OR ¼ 1.92; 95% CI ¼ 0.89-4.14; P ¼ 0.094 for o2 FCGR3B copies and OR ¼ 2.34; 95% CI ¼ 1.04-5.27; P ¼ 0.041 for 42 FCGR3B copies). Next, we adjusted for the effects of age and gender, and found that the ORs for the association of FCGR3B CNV were very similar in multivariate models that included age and gender as covariates (data not shown). Therefore, in all subsequent analyses, we did not include age or gender in the statistical models, and examined the interactive effects of FCGR3B and CCL3L1 CNV on autoimmune diseases.
Modifier effects of CCL3L1 in SLE and primary SS
In previous studies, we found that the copy number of CCL3L1 modified the Kawasaki disease-, SLE-and HIV-1-disease-influencing effects of CCR5 haplotypes (Burns et al., 10 Mamtani et al. 11 and data not shown). Thus, here we sought to determine whether the underlying copy number of CCL3L1 modified the SLE-and SS-influencing effects associated with FCGR3B CNVs. To accomplish this, we stratified subjects on the basis of their CCL3L1 copy number (that is, o2, 2 or 42 copies), and determined the association of the copy number of FCGR3B before (model 1, Table 1 ) and after accounting for the three CCL3L1 genetic backgrounds defined according to copy number (models 2-4, Table 1 ; o2, 2 or 42 CCL3L1 copies). The increased risk of SLE associated with o or 42 FCGR3B copies was evident mainly in those individuals who also possessed two (Table 1 ). In the case of primary SS, the increased risk associated with o2 FCGR3B copies was most evident in individuals who also possessed two CCL3L1 copies, whereas the increased risk associated with 42 FCGR3B copies was evident only when these subjects also possessed o2 CCL3L1 copies ( Table 1) . The results of the Breslow-Day tests (Table 1) indicated that the heterogeneity of FCGR3B ORs across CCL3L1 strata was statistically significant for subject with SS, but not for those with SLE. For the latter group of patients, FCGR3B seemed to be associated with an increased risk independent of the CCL3L1 copy number.
Attributable fractions for FCGR3B
We calculated attributable fractions to determine the extent to which FCGR3B copy number contributed to the susceptibility to SLE or primary SS before and after accounting for the CCL3L1 genetic background. SLE and primary SS of B19 and 17%, respectively, could be attributed to a FCGR3B copy number that deviated from two ( Figure 1c and Table 1 ). Consistent with the data showing that the associations of o or 42 FCGR3B copies is maximal in those with two CCL3L1 copies, the attributable fractions were also greatest in these subjects.
Discussion
Our data suggests an association between both low-and high FCGR3B copy number, and risk of development of SLE and primary SS. These two clinical conditions, although distinct, have some similarities. Both are autoimmune diseases with similar antibody profiles, affect women more frequently than men and similar HLA alleles convey an increased risk of developing SLE and primary SS. [21] [22] [23] [24] Isenberg 25 has argued that 'both SLE and primary SS are overlapping diseases that cannot be segregated by risk factors, etiology, or clinical or serologic manifestations'. The results of our genetic association study extend these parallels between SLE and primary SS, and in doing so, provide additional credence to the CV/MD hypothesis. [18] [19] [20] Previously, we had shown similarities in the genetic determinants that influence HIV-AIDS susceptibility and SLE pathogenesis. 11 This was notable, as SLE and HIV disease share some clinical and immunopathogenic features (reviewed in Mamtani et al.
11
). Together, these findings highlight the growing recognition 20 that diseases that may share immunopathogenic features may also share overlapping genetic determinants of disease pathogenesis. In contrast, we did not find an association between FCGR3B copy number and RA. These findings throw light on common and specific mechanisms by which the copy number of FCGR3B may have a role in the development of different autoimmune diseases.
Another noteworthy feature of our results was that both low-and high FCGR3B copy number was associated with an enhanced risk of SLE and primary SS, a feature that is consistent with the gene balance hypothesis, which posits that both haploinsufficiency and overexpression of a gene may influence disease outcomes. 2 Thus, the biological correlates linked to a low-or high FCGR3B gene dose might contribute to an autoimmune phenotype. In many mammalian species, Fc receptors provide a functional bridge between the humoral and FCGR3B copy number and autoimmune diseases M Mamtani et al cellular branches of the immune system, and have a crucial role in activation and modulation of immune responses. 26 Human FCGR3B is expressed mainly on neutrophils and is essential for tethering of immune complexes to neutrophils. 16 Aitman et al. 15 raise the possibility that a reduced expression of FCGR3B in patients with low FCGR3B copy number may lead to a diminished clearance of immune complexes in SLE, a finding that has been supported by a recent functional study. 27 On the other hand, a high FCGR3B copy number might be associated with increased expression levels, and consequently highly sensitive neutrophils that may initiate an immune response even when the levels of immune complexes are low. Consistent with this thesis, it has been shown, for example, that allelic variants of FCGR3B that are associated with varying density of the cell-surface receptor lead to different levels of phagocytosis of IgG-opsonized erythrocytes. 28 Moreover, when the burden of immune complexes is moderate to high, these sensitive neutrophils may result in a strong cellular immune response, because infiltration of the target tissues with neutrophils sets up a cascade of events beginning with myeloperoxidase deposition and further cellular recruitment of CD4 þ T cells. 29 We found that the risk of SLE and primary SS that can be attributed to a FCGR3B copy number other than two copies was both similar and high (B19 and 17%, respectively). Of note, we had found previously that the deviation from two copies of the CCL3L1 gene is also associated with an increased risk of SLE in several geographically distinct cohorts. 11 In northwestern Colombians examined herein, deviation of the CCL3L1 copy number from the average dose contributed to B28% (95% CI 5.12-46.84) of the risk of developing SLE. A possible explanation for these apparently high estimates of the attributable risk could be that a subset of our study population had a more severe disease phenotype, thereby inflating the strength of association between CNV and SLE. However, considering the wide spectrum of clinical manifestations in the study subjects, a false high estimate of the ORs is unlikely. Therefore, it is possible that the FCGR3B and CCL3L1 CNVs have a key role in modulating the risk of SLE and SS in the study population. Taken together, FCGR3B and CCL3L1 CNV may contribute substantially to SLE susceptibility (attributable fraction for both FCGR3B and CCL3L1 CNV ¼ 45.12% (95% CI 11.52-76.63)). Thus, we propose that a copy number of FCGR3B and CCL3L1 that deviates from a homeostatic diploid state may be an important genomic determinant of risk of autoimmunity.
In our previous work, we found that CCL3L1 is not only associated with the risk of SLE but it also modified the phenotypic (SLE-modifying) effects of CCR5 haplotypes. 11 In this light, we sought to investigate whether CCL3L1 also modifies the disease-influencing effects associated with FCGR3B, as CNVs in both of these genes are associated with the risk of SLE. Extending and amplifying these findings, we found that with the exception of the association between possession of 42 FCGR3B copies and risk of primary SS, all other associations for o or 42 copies of FCGR3B were evident mainly on the genetic background of two copies of CCL3L1. This suggests that there might be an epistatic interaction between FCGR3B and CCL3L1. However, the exact biological mechanisms by which CCL3L1 CNV might influence the effects of FCGR3B are currently unknown. Nevertheless, there is a growing recognition for both the importance of gene-gene interactions in influencing disease phenotype 30, 31 and the presence of many well-described and unknown gene networks that may influence different disease states. 32 In this context, we surmise that CCL3L1-FCGR3B may participate in key immunopathogenic networks that influence autoimmune diseases. Collectively, these findings underscore that autoimmune and other disease states may be the result of more complex gene-gene interactions than heretofore recognized. In addition, our findings may have translational value as they suggest that FCGR3B might be a potential therapeutic target for autoimmune diseases such as SLE.
Materials and methods

Study population
The study sample comprised of 774 individuals. This included 132 (83.54%) women and 26 (16.46%) men with RA; their mean age ± s.d. (standard deviation) was 48.97±12.24 years, the mean duration of disease was 11 ± 8.1 years and 78.2% tested positive for rheumatoid factor. Extra-articular manifestations were registered in 45.9% of subjects.
There were 143 (97.90%) women and 3 (2.10%) men with SLE; their mean age ± s.d. was 32.77 ± 11.15 years, the mean duration of disease was 7.5±7 years, and antinuclear antibodies, anti-DNA, anti-Sm, anti-RNP, anti-Ro and anti-La antibodies were positive in 99.2, 72.4, 35.4, 63.4, 38.2 and 15.2% subjects, respectively. Lupus nephritis was detected in 41.3% of the SLE patients.
All the 61 patients with primary SS were women; their mean age ±s.d. was 52.42±13.63 years and the mean duration of disease was 6.4 ± 5.2 years. During the course of the disease, all patients presented with sicca symptoms, 59% had vascular-inflammatory involvement and 19.7% had internal-organ manifestations. All primary SS patients had a lymphocytic infiltrate in minor salivary glands with a focus score 41, and anti-Ro and anti-La antibodies were detected in 73.8 and 52.5%, respectively. All patients with autoimmune diseases met the international classification criteria for their respective disease. [33] [34] [35] The control group included 409 individuals without a history of chronic inflammatory autoimmune or infectious diseases; they were matched to patient groups by ethnicity and socioeconomic status, and were unrelated to patients. Their mean age was 45.84±13.20 years and 93.4% were women.
All the study subjects were enrolled at the Cellular Biology and Immunogenetics Unit of the 'Corporació n para Investigaciones Bioló gicas' (CIB), in Medellin, and were of Spanish ancestry, originating from the northwestern population of Colombia known as the Paisa community. 36 Anthropological and historical studies describe this population as the most clearly defined in Colombia because of the relative genetic isolation maintained until the late 19th century. Paisa ancestral ethnic component consists of 85% Caucasian and 15% Amerindian, whereas admixture between Paisa and FCGR3B copy number and autoimmune diseases M Mamtani et al
African populations has been documented as not significantly greater than zero. 36, 37 Previous work from our group has shown the homogeneity of our cohorts and control group. 38, 39 Exclusion criteria consisted of hematological disorders, active infection or breastfeeding. This research was conducted in compliance with resolution 008430 of 1993 of the Ministry of Health of Colombia, and was classified as minimal risk research. This study was also approved by the institutional review board at CIB and the University of Texas Health Science Center at San Antonio, USA.
Quantification of FCGR3B copy number
Genotyping for the copy number of FCGR3B was performed using real-time PCR with the ABI/PRISM 7700 or 7900 Sequence Detector System (PE, Applied Biosystems, Foster City, CA, USA). The system detected the emitted fluorescence as FAM (6-carboxyfluorescein, 6-FAM) from the probe detecting FCGR3B and VIC from the probe detecting the b-globin gene during amplification. 0 (synthesized by Applied Biosystems). The methods of genotyping FCGR3B copy number are similar to those used to quantify the copy number of CCL3L1, as described previously. 5 
Statistical analyses
We used the w 2 -test to determine the significance of the differences in the distribution of the copy number of FCGR3B between cases and controls. Next, we used unconditional multiple logistic regression analyses to assess the association between the copy number of FCGR3B and the risk of developing SLE, RA and primary SS in separate regression models. ORs were used as an estimate of the relative risk, and were determined along with their 95% CIs using unconditional logistic regression analyses. We also studied the association of copy number of FCGR3B with the risk of lupus nephritis and elevated autoantibody titers in the SLE cohort. To test whether the copy number of FCGR3B is independently associated with the risk of SLE, RA and primary SS, we included the copy number of CCL3L1 in a single multivariate logistic regression model along with FCGR3B. In addition, we determined whether the association of the CNV in FCGR3B differed according to the genetic background of CCL3L1 CNV. Next, we estimated the attributable fraction as p(ORÀ1)/ (p(ORÀ1) þ 1), 40 where p is the proportion of controls with FCGR3B copy number other than the average and OR represents the OR estimated from logistic regression analysis. Lastly, we formally tested whether the ORs reflecting association of FCGR3B CNV with the risk of SLE and SS were heterogeneous across the CCL3L1 gene copy number using the Breslow-Day test of homogeneity. All the statistical analyses were conducted using the Stata 10.0 (College Station, TX, USA) statistical software.
